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Characterization of Cholesterol and Drug Ligand Interactions with Trans-
locator Protein 18 KDA (TSPO) from Rhodobacter Sphaeroides
Fei Li, Lance Valls, Shelagh Ferguson-Miller.
Biochemistry and Molecular Biology, Michigan State University, East
Lansing, MI, USA.
The mitochondrial outer membrane protein Translocator Protein 18 kDa
(TSPO), previously known as the peripheral benzodiazepine receptor (PBR),
has been proposed to be a key component of the cholesterol transport system
in mitochondria and a rate limiting step for steroidogenesis. Dysregulation of
neurosteroids generation involving TSPO has been shown to be related to a va-
riety of neurological and psychiatric diseases, including Alzheimer’s disease,
Parkinson’s disease, as well as bipolar disorder. In addition, ligands of TSPO
are widely used for imaging brain injury and inflammation, areas in which
TSPO is highly expressed. A natural human single-nucleotide polymorphism
(SNP) gives rise to a mutation, A147T, within the proposed cholesterol recog-
nition site (CRAC). This mutation leads to altered ligand binding and has
recently been reported to reduce pregnenolone production and to be associated
with bipolar disorder. The same mutation is reported to inhibit a proposed
TSPO catalyzed degradation of prototoporphyrin IX. TSPO from Rhodobacter
sphaeroides (RsTSPO) shares high sequence similarity with the human protein
but differs in the region of the SNP and shows significantly lower cholesterol
binding. To better understand the interaction of TSPO with cholesterol,
porphyrin and other ligands, we expressed and purified the recombinant
RsTSPO and several mutants in the cholesterol binding region. Binding prop-
erties were investigated with a sensitive tryptophan fluorescence quenching
assay and the interactions were characterized by X-ray crystallography.(Sup-
ported by the MSU Center for Mitochondrial Science and Medicine, a Strategic
Partnership Grant fromMichigan State University Foundation and GM26916 to
SFM).
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Monitoring Intramembrane Proteolytic Cleavage Reactions using Isotope-
Assisted Vibrational Interrogation of Membrane Embedded (IVIBE)
Proteins
Mia Brown1, Renee D. JiJi2, Iban Ubarretxena-Bilandia3, Jason W. Cooley2.
1University of Missouri Columbia, Columbia, MO, USA, 2Chemistry,
University of Missouri Columbia, Columbia, MO, USA, 3Icahn School of
Medicine at Mt. Sinai, New York City, NY, USA.
While several intramembrane cleaving proteases (iCliPs), enzymes that carry
out proteolysis reactions within the membrane interior, have had their struc-
tures solved, basic biochemical questions such as what determines a substrate
and how cleavage site is dictated remain. However, our inability to monitor
enzyme-substrate interactions in a lipid environment is the dominant factor
limiting our understanding of the central questions associated with these en-
zymes. Specifically, while there are many excellent techniques for the charac-
terization of membrane proteins, many of them are only amenable to steady
state measurements, require removal from the membrane, or are too low reso-
lution to offer detailed information about changes in structure and environment.
Here we offer a new method by which to observe structural fluctuations of the
enzyme and the substrate during cleavage reactions within a membrane envi-
ronment: isotope-assisted vibrational interrogation of bilayer-embedded sys-
tems (iVIBE). Deep UV resonance Raman (DUVRR) spectroscopy has
previously been used to observe structural and environmental changes in
both soluble and membrane proteins. Now, using an isotopically labeled prote-
ase and an unlabeled substrate we can resolve the spectral responses from each
protein, allowing us to observe the cleavage reaction over time and determine
the binding site, or structural fate of the substrate.
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Investigating Ligand-Modulation of GPCR Activation Pathways
Morgan Lawrenz1, Kai Kohlhoff2, Diwakar Shukla1, Greg Bowman3,
Russ Altman1, Vijay Pande1.
1Stanford University, Stanford, CA, USA, 2Google Inc, Mountain View, CA,
USA, 3University of California, Berkeley, Berkeley, CA, USA.
Molecular dynamics simulations can provide tremendous insight into atomistic
details of biological mechanisms, but micro- to milliseconds timescales are his-
torically only accessible on dedicated supercomputers. We demonstrate that
cloud computing is a viable alternative, bringing long timescale processes
within reach of a broader community. We used Google’s Exacycle cloud
computing platform to simulate an unprecedented 2 milliseconds of dynamics
of the b2 adrenergic receptor (b2AR)_a major drug target G protein-coupled
receptor (GPCR). Markov state models aggregating these independent simula-
tions into a single statistical model are validated by previous computational and
experimental results and provide the first atomistic description of multipleGPCR activation pathways. We show that agonists and inverse agonists interact
differentially with these pathways, creating an opportunity for developing
drugs that interact more closely with diverse receptor states, for overall
increased efficacy and specificity.
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Crystal Structure of MraY, an Essential Membrane Enzyme for Bacterial
Cell Wall Synthesis
Ben C. Chung, JInshi Zhao, Robert Gillespie, Do Yeon Kwon, Ziqiang Guan,
Jiyong Hong, Pei Zhou, Seok-Yong Lee.
Duke University, Durham, NC, USA.
The Phospho-MurNAc-pentapeptide translocase (MraY) is a prokaryotic
membrane-spanning enzyme involved in an essential process of peptidoglycan
synthesis: transfer the precursor phosphor-MurNAc-pentapeptide to carrier
lipid undecaprenyl phosphate. MraY belongs to a subfamily of the
polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase (PNPT)
superfamily whose members are involved in various biological processes
including eukaryotic N-linked glycosylation. MraY has been a target for anti-
biotics development for its essentiality and specificity in bacteria. Therefore
atomic structure of MraY can provides valuable mechanistic information that
can aid development of new antibiotics. We report the crystal structure of
MraY from Aquifex aeolicus (MraYAA), the first structure of the PNPT super-
family, at 3.3 A˚ resolution. The crystal structure, together with crystallographic
and functional studies, reveals the architecture of MraYAA, the location of
Mg2þ at the active site and the putative binding sites of both substrates. Our
crystallographic studies provide insights into the mechanism of how MraY at-
taches a building block of peptidoglycan to a carrier lipid.
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Combining Modelling and Site-Directed Mutagenesis to Explore Agonist
Binding to Human Orexin Receptors
Alexander Heifetz1, Oliver Barker1, G. Benjamin Morris2, Richard J. Law1,
Mark Slack3, Philip C. Biggin2.
1Evotec, Abingdon, United Kingdom, 2Oxford University, Oxford, United
Kingdom, 3Evotec, Hamburg, Germany.
Orexin-1 (OX1) and orexin-2 (OX2) are class A G-protein Coupled Receptors
(GPCR)s located predominantly in the brain and are linked to a range of
different physiological functions, including the control of energy metabolism
and regulation of the sleep-wake cycle. The natural agonists for both receptors
are two small peptides, Orexin A and Orexin B. Both peptides have activity at
both receptors. Although no experimentally-derived structure has yet been pub-
lished for the receptors in complex with either agonists or antagonists, a large
amount of site-directed mutagenesis (SDM) has been reported and has provided
important insight into the key determinants of agonist and antagonist activity.
In drug-discovery, a working three-dimensional model can provide an intuitive
way forward to explore new compounds. Thus we developed homology models
that utilized existing SDM data, which we then explored further with MD simu-
lation and ensemble-flexible docking to generate binding poses of the Orexin
peptides in the OX receptors. We were then able to test the resulting poses
with additional SDM experiments. As part of our modelling procedure we
also developed a new method to analyze the structural data generated within
an MD simulation to help distinguish between different GPCR substates. Our
work demonstrates how this new method of structural assessment for GPCRs
can be used to provide a working model for peptide-Orexin receptor
interaction.
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Kinetic Exclusion Analysis (KinExa) of Avidity Enhancement of a Multi-
Valent Adnectin Binding to Clustered Receptors on CHO Cells
Lumelle A. Schneeweis1, Sandra V. Hatcher1, Bryan Barnhart1,
Thomas R. Glass2, Lin Cheng1, Benjamin Blum3, Eric Lawrence1,
Rolf Ryseck1, Ray Camphausen3, Bozena M. Abramczyk1, Anthony Della
Pietra1, Martin J. Corbett1, Thomas McDonagh3, Michael L. Doyle1,
James Bryson1.
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Sapidyne Instruments, Inc.,
Boise, ID, USA, 3Bristol-Myers Squibb, Waltham, MA, USA.
Multivalency is a strategy used in nature to gain avidity. A variety of cell sur-
face receptors are known to cluster at the cell surface via protein or lipid (raft)
interactions. Analytical methods to measure the effect of avidity as it exists at a
cell surface are challenging. Kinetic Exclusion Analysis (KinExA) is a sensi-
tive immunodetection analytical technique for measuring solution affinity. Ad-
nectinsTM are a proprietary type of targeted biologic derived from human
fibronectin. Adnectin-A was selected with mRNA display (PROfusionTM) to
bind specifically to cell surface receptor X, and was formated as a multivalent
fusion protein. To determine the affinity and avidity of Adnectin-A for receptor
X clustered on cells, both the human and cynomolgus monkey homoloques of
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acterized by FACS and then scaled up for KinExA binding studies. KinExA has
been used to measure binding affinity of Adnectin-A to the cell surface ex-
pressed receptor X to measure the effect of avidity of the multivalent adnectin
binding to receptor clusters. As controls for the functional activity of the
Adnectin-A and the affinity of the monovalent interaction, the same KinExa
assay was used, substituting the soluble receptor X extracellular domain for
the transfected CHO cells. The binding avidity measured by KinExA for
CHO expressed receptor is 14 pM for both species of receptor X. However,
the affinity of Adnectin-A for monovalent soluble Receptor X was quite
different between the species suggesting that avidity due to receptor clustering
equilizes the functional avidity at the cell surface.
Platform: Voltage-gated K Channels: Activation/
Inactivation Mechanisms
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A-Type Kv4 Channel Closed-State Inactivation is Modulated by the
Tetramerization Domain Interacting with Auxilary KChIP4a
Yi-Quan Tang1, Fan Yang2, Jingheng Zhou1, Jie Zheng2, KeWei Wang1.
1Peking University, Beijing, China, 2University of California at Davis, Davis,
CA, USA.
A-type Kv4 potassium channels undergo a conformational change towards a
non-conductive state at negative membrane potentials, a dynamic process
known as closed-state inactivation (CSI). CSI causes inhibition of channel ac-
tivity without prerequisite of channel opening, thus providing a dynamic regu-
lation of neuronal excitability, dendritic signal integration and synaptic
plasticity. However, the structural determinants underlying Kv4 CSI remain
largely unknown. We have recently demonstrated that auxiliary KChIP4a sub-
unit contains an N-terminal Kv4 inhibitory domain (KID) that directly interacts
with Kv4.3 channels to enhance CSI. In this study, we utilized the FRET two-
hybrid mapping and BiFC-based screening combined with electrophysiology,
and identified the intracellular tetramerization (T1) domain that functions to
suppress CSI and serves as a receptor for the binding of KID. Disrupting
Kv4.3 T1-T1 interaction by mutating C110A within the C3H1 motif of T1
domain facilitated CSI, and ablated the KID-mediated enhancement of CSI.
Furthermore, replacing the characteristic C3H1 motif of Kv4.3 T1 domain
with the T1 domain from Kv1.4 without the C3H1 motif or Kv2.1 with the
C3H1 motif resulted in channels functioning with enhanced or suppressed
CSI, respectively. Taken together, our findings reveal a novel role of the T1
domain in suppressing Kv4 CSI with the C3H1 motif functioning to stabilize
the channel activation gate; and KChIP4a KID directly interacts with the T1
domain to relieve the stabilization, leading to facilitation of CSI and inhibition
of channel function.
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Two-in-One: Activation and Inactivation at the Intracellular Gate of a Kv
Channel
Manuel Covarrubias1, Jeffrey D. Fineberg2.
1Neuroscience, Jefferson Medical College of Thomas Jefferson University,
Philadelphia, PA, USA, 2Physiology and Molecular Biophysics, Jefferson
Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
N-type and P/C-type inactivation are firmly established mechanisms of inac-
tivation in voltage-gated Kþ (Kv channels). However, Kv4.x channel com-
plexes, which undergo fast preferential closed-state inactivation (CSI;
Fineberg et al., 2012, JGP 140.5:513-527), appear to use a distinct but un-
known inactivation mechanism. Previously, we hypothesized that a weak
interaction between the voltage sensing domain and the intracellular activa-
tion gate underlies CSI (Ba¨hring & Covarrubias, 2011, J Physiol 589:461-
79). Thus, CSI is essentially governed by the intracellular activation gate,
which fails to open and adopts an inactivated conformation. To directly test
this hypothesis, we investigated the heterologously expressed Kv4.1 ternary
channel complex including accessory subunits KChIP1 and DPP6, and ex-
ploited the ‘‘trap-door’’ paradigm of the activation gate. The results show
that Kv4.1 inactivation traps intracellularly applied quaternary ammonium
blockers (bTBuA and TBuA) inside the channel’s pore. The trapped blockers
can only escape if the channels are opened again by subsequent depolariza-
tions. By contrast, inactivation cannot trap TEA, whose binding kinetics is
faster than that of channel gating. Moreover, under identical conditions, a
Shaker Kv channel (ShB-T449K) known to exhibit fast P/C-type inactivation
cannot trap bTBuA. These findings conclusively suggest that the intracellular
activation gate of the Kv4.1 ternary channel complex plays a novel dual role,
controlling both activation and inactivation. Supported in part by NIH grant
R01 NS032337 (MC).94-Plat
Development and Validation Studies of Universal Pharmacophore Models
for hERG Channel Openers
Serdar Durdagi1,2, Matthew Patterson2, Sergei Y. Noskov2.
1Department of Biophysics, Bahcesehir University, Faculty of Medicine,
Istanbul, Turkey, 2Biological Sciences, Institute for Biocomplexity and
Informatics, University of Calgary, Calgary, AB, Canada.
The intra-cavitary drug blockade of hERG channel, a common off-target for
many drugs, have been extensively studied both experimentally and theoreti-
cally. Structurally diverse ligands inadvertent blockade of rapid component
of delayed rectifying Kþ currents are potentially pro-arrhythmic and may
lead to drug-induced long QT syndrome-LQTS. There are a number of natural
strategies for rational drug design; one dubbed the ‘‘passive’’ approach avoids
block of hERG1 whereas the ‘‘proactive’’ strategy designs treatments to acti-
vate the channel. While ‘‘passive’’ approach has been developed for decades,
studies of structural mechanisms of hERG channel activation by small mole-
cules are truly novel. Accordingly, design of the hERG openers or current ac-
tivators may offer a momentum for modern anti-arrhythmia drug development.
Significant number of small molecules with capacity for hERG activation was
identified in mandatory hERG screens. To establish possible correlation be-
tween activators structure and reactivity, we attempted to construct a universal
pharmacophore model for hERG channel openers using PHASE protocol. The
biochemical data on 38 Kþ channel activators are used in training and test sets.
These compounds span a wide range of structurally different chemotypes with
~10^5-fold variances in binding affinity, which is sufficient for statistically
sound model. A developed five sites AAHHR (A, hydrogen-bond accepting,
H, hydrophobic, R, aromatic) pharmacophore model has showed reasonable
high statistical results compared to other constructed models and was selected
for steric and electrostatic contour maps analysis. The predictive power of the
model was also tested with 6 external test-set (as true unknowns) compounds.
Pharmacophore model is also combined with previously developed receptor-
based homology model of hERG K channel and novel activators are generated
and screened. The developed ligand-based models may serve as a basis for the
synthesis of novel potential therapeutic hERG activators.
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N-Terminal Regulation of hERG1 KD Channel Deactivation
Steven J. Thomson, Angela Hansen, Michael C. Sanguinetti.
Nora Eccles Harrison Cardiovascular Research and Training Institute,
University of Utah, Salt Lake City, UT, USA.
Slow deactivation of hERG1 (Kv 11.1) potassium channels maintains IKr dur-
ing final repolarization of the cardiac action potential and opposes asynchro-
nous early depolarization. Inherited point mutations in hERG1 that accelerate
deactivation of IKr cause long QT syndrome (LQTS), a disorder of ventricular
repolarization that increases the risk of lethal cardiac arrhythmia.
The intracellular N-terminal domain of hERG1 is known to be essential for
slow deactivation. Deletion of the entire (~350 residues) or just the initial 16
residues of the N-terminus accelerates deactivation 10-fold. The same effect
is achieved by neutralization of the charged residues, Arg4 or Arg5. How
many of the 4 N-termini are required to slow channel deactivation is unknown.
hERG1, like other Kv channels, is a homotetramer. By repeatedly linking the
C-terminal of one subunit to the N-terminal of the next subunit we constructed
concatenated hERG1 tetramers. A variety of homomeric and heteromeric
concatenated tetramers were characterized (i.e., WTn/R4A:R5A(4-n); where
n = 1 to 4). The concatenated channel containing a single R4A/R5A subunit
and 3 wild-type subunits deactivated as fast as the concatenated channel con-
taining only R4A/R5A subunits. The LQTS-associated mutation R56Q, located
in the N-terminal of hERG1 was also studied. Again, a concatenated tetramer
containing a single mutant subunit deactivated as fast as channels with R56Q
mutations in all four subunits. Our results show that all 4 N-termini are required
to mediate slow deactivation in wild-type hERG1 channels.
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Lipid Affinity to the Voltage-Gated Potassium Channel KvAP
Elise Faure1, Christine Thompson2, Rikard Blunck1,2.
1Physiology, Universite´ de Montre´al, GE´PROM, Montre´al, QC, Canada,
2Physique, Universite´ de Montre´al, GE´PROM, Montre´al, QC, Canada.
Voltage-gated potassium channels (KV) are formed by a central conducting
pore surrounded by four voltage sensor domains. Functional studies have re-
vealed that biophysical properties of lipid molecules in the channels environ-
ment can have strong effects on the activity of KV channels. Here, we
investigated the influence of different lipids as well as their affinity to KvAP
channels. We carried out electrophysiology measurements by fusing vesicles
containing purified channels into planar lipid bilayers with varied lipid compo-
sitions. We found that KvAP properties are mainly determined by the lipid
